Passa al contenuto
Merck

The potential of DMXAA (ASA404) in combination with docetaxel in advanced prostate cancer.

Expert opinion on investigational drugs (2007-12-22)
Mark J McKeage
ABSTRACT

5,6-Dimethylxanthenone-4-acetic acid (DMXAA) is a vascular disrupting agent that has demonstrated efficacy in combination with taxane-based chemotherapy in patients with advanced cancer. Complementary modes of action, a lack of pharmacokinetic interaction and distinct adverse effect profiles provide a strong rationale for combining these anticancer agents. In a Phase II trial in men with hormone refractory prostate cancer, DMXAA (ASA404) in combination with docetaxel achieved a prostate-specific antigen response in more patients than docetaxel therapy alone, and was generally well tolerated. Further clinical evaluation of this combination in this patient population is warranted.

MATERIALI
N° Catalogo
Marchio
Descrizione del prodotto

Sigma-Aldrich
DMXAA, ≥98% (HPLC), solid